| Name | Bazinaprine |
| Description | Bazinaprine is a selective, reversible monoamine oxidase inhibitor (MAOI) that is a candidate compound for the treatment of depression. Bazinaprine showed strong inhibitory effect on type A monoamine oxidase and weak inhibitory effect on type b monoamine oxidase. Bazinaprine is reversible in vivo, but not in vitro. |
| In vitro | Bazinaprine(SR 95191) inhibits MAO-A in a time-dependent manner in vitro and appears to be irreversible.[1] The inhibition of brain MAO-A, but not MAO-B, by SR 95191 was time dependent, with a 19-fold decrease in the IC50 values being observed over a 30-min incubation period (140 to 7.5 μM).[2] |
| In vivo | Bazinaprine (1–100 mg/kg, p.o.) antagonized, in a dose-dependent fashion, the irreversible inhibition of brain and liver MAO-A induced by phenelzine.[2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 22.5 mg/mL (72.73 mM), Sonication is recommended.
|
| Keywords | SR 95191 | MAO | Bazinaprine |
| Inhibitors Related | Safinamide | 1,4-Naphthoquinone | 4-Chlorochalcone | Paeonol | Hydroxylamine hydrochloride | Isatin | Methylene Blue trihydrate | β-Aminopropionitrile | Aminoacetone hydrochloride | Allylthiourea | D-(-)-Quinic acid | Amitraz |
| Related Compound Libraries | Mitochondrial Membrane Protein-Targeted Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | ReFRAME Related Library | CNS-Penetrant Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Bioactive Compounds Library Max |
United States
